12:59 Tue 15 Dec 2020
Sareum Holdings PLC - Result of AGM
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Results of AGM
| Ordinary resolutions | Votes For | % | Votes Against | % | Votes Total | % of ISC Voted | Votes Withheld |
| | | | | | | | |
| 1. Receive the Annual report and accounts for the Company | 236,539,335 | 99.97 | 76,912 | 0.03 | 236,616,247 | 7.24 | 317,483 |
| 2. Approve the Directors' Remuneration Report | 225,264,050 | 98.71 | 2,946,682 | 1.29 | 228,210,732 | 6.98 | 8,722,998 |
| 3. Re-elect Dr | 225,888,456 | 95.36 | 10,980,647 | 4.64 | 236,869,103 | 7.25 | 64,627 |
| 4. Re-elect Dr | 236,331,048 | 99.77 | 538,055 | 0.23 | 236,869,103 | 7.25 | 64,627 |
| 5. Appoint Shipleys LLP as auditor | 236,450,012 | 99.80 | 483,718 | 0.20 | 236,933,730 | 7.25 | 0 |
| 6. Directors' authority to allot new shares | 229,589,440 | 97.03 | 7,026,807 | 2.97 | 236,616,247 | 7.24 | 317,483 |
| Special Resolution | | | | | | | |
| 7. Disapplication of pre-emption rights | 229,229,425 | 96.90 | 7,322,195 | 3.10 | 236,551,620 | 7.24 | 382,110 |
ISC - Issued Share Capital
The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)
For further information, please contact:
| Sareum Holdings plc
|
01223 497 700 |
| Strand Hanson Limited (Nominated Adviser)
|
020 7409 3494 |
| Hybridan LLP (Nominated Broker)
|
020 3764 2341 |
| Citigate Dewe Rogerson (Financial PR) |
020 7638 9571 |
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
